Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management (Q37832199)

24 August 2017

1 reference

title

Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management (English)

1 reference

24 August 2017

0 references

1

Morie A Gertz

1 reference

PubMed ID

21264900

24 August 2017

language of work or name

1 reference

1 February 2011

1 reference

American Journal of Hematology

24 August 2017

1 reference

24 August 2017

86

1 reference

24 August 2017

2

1 reference

24 August 2017

180-186

1 reference

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy

24 August 2017

1 reference

Currents concepts on the immunopathology of amyloidosis

21 January 2018

1 reference

Pitfalls in the diagnosis of primary amyloidosis

21 January 2018

1 reference

Systemic amyloidosis: a challenge for the rheumatologist

21 January 2018

1 reference

Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature.

21 January 2018

1 reference

Echocardiographic evaluation of cardiac amyloid

21 January 2018

1 reference

Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.

21 January 2018

1 reference

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

Prevalence of monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

Prevalence and origin of amyloid in kidney biopsies.

21 January 2018

1 reference

Amyloid in endomyocardial biopsies.

21 January 2018

1 reference

Amyloid in bone marrow smears of patients affected by multiple myeloma

21 January 2018

1 reference

Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis

21 January 2018

1 reference

Laryngeal amyloidosis causing hoarseness and airway obstruction

21 January 2018

1 reference

Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study

21 January 2018

1 reference

The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature

21 January 2018

1 reference

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

21 January 2018

1 reference

Glycosaminoglycans are part of amyloid fibrils: ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold.

21 January 2018

1 reference

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

Cardiac amyloidosis: approaches to diagnosis and management

21 January 2018

1 reference

Prognostic significance of strain Doppler imaging in light-chain amyloidosis.

21 January 2018

1 reference

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis

21 January 2018

1 reference

Treatment of immunoglobulin light chain amyloidosis

21 January 2018

1 reference

Serum uric acid: novel prognostic factor in primary systemic amyloidosis

21 January 2018

1 reference

Treatment of "primary" renal amyloidosis with melphalan.

21 January 2018

1 reference

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

21 January 2018

1 reference

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review

21 January 2018

1 reference

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

Transplantation for amyloidosis

21 January 2018

1 reference

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

21 January 2018

1 reference

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

21 January 2018

1 reference

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant

21 January 2018

1 reference

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging

21 January 2018

1 reference

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

21 January 2018

1 reference

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.21934

1 reference

24 August 2017

1 reference

PubMed ID

21264900